Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 8/20 | 0.53 |
| ▸ | CDK2 | P24941 | 5/20 | 0.50 |
| ▸ | CDK4 | P11802 | 3/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 2/20 | 0.44 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7978517 | 0.92 | IGF1R (0.53) | IGF1RCDK2CDK4CCNE1CDK1 | |
| SCHEMBL700837 | 0.91 | CDK2 (0.48) | IGF1RCDK2CDK4CCNE1CDK1 | |
| SCHEMBL702867 | 0.87 | HDAC1 (0.58) | IGF1RCDK2CDK4CCNE1CDK1 | |
| SCHEMBL699814 | 0.87 | CDK2 (0.51) | IGF1RCDK2CDK4CCNE1CDK1 | |
| SCHEMBL703707 | 0.86 | CDK2 (0.47) | IGF1RCDK2CDK4CCNE1CDK1 | |
| SCHEMBL700744 | 0.85 | CDK2 (0.49) | CDK2CDK4CCNE1CDK1 | |
| SCHEMBL703004 | 0.85 | HDAC1 (0.51) | IGF1RCDK2CDK4CCNE1CDK1 | |
| SCHEMBL7975343 | 0.83 | CDK2 (0.51) | IGF1RCDK2CDK4CCNE1CDK1 | |
| SCHEMBL655254 | 0.83 | IGF1R (0.42) | IGF1RCDK2CDK4CCNE1CDK1 | |
| SCHEMBL699629 | 0.82 | CDK2 (0.51) | CDK2CDK4CCNE1CDK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | IGF1R 1719/4885CDK2 16/4885CDK4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.